Pregablin for Anxiety-comorbidity in Patients With Schizophrenia
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The PACS study aims to investigate the efficacy and tolerability of pregabalin for
schizophrenic patients that suffer from comorbid anxiety.
The study design is an 8 week flexible dosage, randomized placebo controlled.
The study population is patients diagnosed with ICD-10 schizophrenia and age 18-65. Patients
are recruited from outpatient clinics from entire Denmark.
Phase:
Phase 4
Details
Lead Sponsor:
University of Aarhus
Collaborators:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University GCP-unit at Aarhus University Hospital, Aarhus, Denmark Pfizer The Hospital Pharmcacy North Denmark Region, Denmark